Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ligand Announces Closing of Convertible Senior Notes Offering
-
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
-
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
-
Ligand Announces 2026 Investor Day in New York City
-
Ligand to Participate in June Investor Conferences
-
Ligand Reports First Quarter 2026 Financial Results
-
Ligand to Participate in May Investor Conferences
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
-
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS